Invitrogen Launches 60 Division Arrested Cell Lines
Product News Jul 13, 2007
Invitrogen Corporation launches the first suite of 60 division arrested cell lines for screening a broad range of therapeutic targets.
Generated through a proprietary treatment of dividing cells, division arrested cells do not require lengthy and laborious cell culture procedures to prepare live cells for screening assays. Division arrested cells may be plated and assayed within 24 hours of thawing, and cell numbers increase only marginally after plating, thereby removing the variability caused by cell division during the course of an assay and providing more consistent results.
Division arrested cells show agonist-induced responses virtually indistinguishable from that of dividing cells, and exhibit no toxicity or apparent changes in signal transduction, ensuring researchers obtain the correct pharmacological profile.
The collection includes a broad range of cell lines developed for functional cell-based assays of G-protein coupled receptors, nuclear hormone receptors and hERG. The cell lines are available in two configurations: 1 x 384-well plate assay kits (including detection reagents) for small scale screening or evaluation purposes, and 10 x 384-well-plate kits for small to large scale screening.
Invitrogen acquired division arrest technology last year through the acquisition of Sentigen Corporation. As part of the Sentigen transaction, Invitrogen owns the patent family which includes U.S. Patent No. 7,045,281 and Australian Patent No. 2003270073.